Close Menu

Breaking News

The team will expand MyCartis' real-time Evalution platform to allow users to quantify organ damage next to the degree of inflammation.

The French company develops software solutions for digital pathology, including software for microscopic and macroscopic image management.

Nationwide Labs will use the PathogenDx array system for rapid strain identification of skin and foot fungi.

The firm said that its molecular diagnostics sales growth in the quarter was negatively impacted by non-governmental organization purchasing patterns in Africa.

Quest will provide CHS of Long Island with lab testing as well as management of lab equipment, supplies, and procurement processes.

Fulgent will use its Parkinson's disease NGS panel to target seven genes linked to the condition and generate curated reports for doctors and researchers.

Clinical Pathology Laboratories said information on 2.2 million patients had been exposed in the same data breach that impacted millions of Quest and LabCorp patients.

Treatment of Chagas disease can be lengthy and there is currently no available method to confirm whether a patient has been cured, according to the firm.

The financing will go toward ongoing commercialization of the firm's autoimmune tests and therapeutics promotion business.

Evercore noted that while Qiagen is on target to hit previously issued 2020 financial targets, its recently issued long-term guidance for 2023 is less of a sure thing.

The company's cofounders have developed methods for analyzing genetic material from fetal trophoblast cells isolated from the cervix.

The company will market Inivata's InVision liquid biopsy assays to insured and self-pay patients across the region.

23andMe customers who have one of three common variants identified in reports can choose six family members to receive health and ancestry test kits.

Mirnax will use Arcis' nucleic acid sample preparation and preservation technology to improve the stability of miRNA biomarkers for early disease detection.

Additionally, Cancer Genetics noted that last week it sold off its clinical laboratory business to siParadigm, a specialty reference laboratory, for about $1 million.

The test could potentially enable labs to bring resistance testing in house, rather than send testing out to Canada's National Microbiology Laboratory.

The test measures levels of seven autoantibodies to tumor-associated antigens and is designed to detect all forms of lung cancer at any stage.

The iC-GN Assay detects target DNA and identifies gram-negative organisms associated with gram-negative bacteremia, and three antibiotic-resistance markers. 

Nestlé Health said that employees of Prometheus are becoming employees of Precision IBD, with the exception of those working in its point-of-care diagnostic business.

Quest has made a strategic investment of an undisclosed amount in Sharecare, and Sharecare has named Quest its preferred laboratory partner.

The company — develops tests for the early detection of cancer and other diseases in whole blood — is targeting C$3.7 million in a private placement financing round.

Within the "Big Three" conditions, misdiagnoses related to stroke, sepsis, and lung cancer accounted for the most high-severity diagnostic error cases.

 

The latest NYS Department of Health approval expands the company's CT/NG testing to samples from multiple relevant body sites.

The firm said that the system's automation and flexibility will help centers be more productive within a testing specialty that can require extensive hands-on time.

Pages